Event on

The importance of LF-LAM technology in TB diagnosis among patients with advanced HIV diagnosis

Background

According to the World Health Organization (WHO), in 2017 the risk of developing TB for the 38 million people living with HIV was 18 times higher than the risk for the rest of the global population. In 2019, a total of 456 426 cases of TB were notified among HIV-positive people and about 208 000 deaths from TB were reported in the same population.

In 2019, the WHO Global TB Programme provided updated clinical guidance and management on the use of the LF-LAM assay for the diagnosis of TB in PLHIV. The implementation of LF-LAM in patients with advanced HIV disease has showed promise as a simple, inexpensive POC platform. The webinar serves to provide insight into practical implementation of LF-LAM and demonstrate the successful integration in the South African context.

PRESENTATIONS

© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only. COL-10481